Symptomdx.

Get Started

Bipolar Disorder (Manic Episode)MANAGEMENT

PSYCHIATRIC PRESENTATIONS · 12 SECTIONS

⚲

779 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Acute anxiety Acute psychosis Agitation-behavioral emergency Anorexia Nervosa (Medical Complications)Bipolar disorder Bipolar Disorder (Depressive Episode)Bipolar Disorder (Manic Episode)Bulimia Nervosa (Medical Complications)Catatonia Conversion disorder Dementia and behavioral crisis Factitious Disorder Failure to Cope (Social)Failure to Thrive Generalized Anxiety Disorder Homicidal Ideation Major Depressive Disorder Major depressive episode Malingering Neuroleptic malignant syndrome Panic Attack Post-Traumatic Stress Disorder (Acute)Schizophrenia Exacerbation Suicidal Ideation Suicidal ideation and attempt Suicide Attempt

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp53

Immediate Priorities

›Psychiatric emergency recognition

›Acute mania with psychosis or aggression

›Hallucinations or delusions present

›Assaultive or threatening behavior

›Severe psychomotor agitation

›Imminent safety threats

›Suicidal ideation — suicide risk 20-30x general population

›Homicidal ideation or violent intent

›Complete loss of judgment with dangerous behavior

›Organic or medical emergency masquerading as mania

›Altered sensorium suggesting delirium

›Focal neurologic deficits

›Fever suggesting encephalitis or sepsis

Stabilization and Safety

›Immediate safety measures

›1:1 observation for agitated or dangerous patients

›Remove dangerous objects from environment

›Quiet low-stimulation room if available

›De-escalation techniques as first-line approach

›Calm, non-confrontational communication

›Avoid direct power struggles

›Restraints only when de-escalation fails and safety is at risk

›Least restrictive appropriate option

›Continuous monitoring during restraints

›Acute agitation management

›Lorazepam 1-2 mg PO or IM for acute agitation

›May repeat every 30-60 minutes as needed

02History/hx70

Mood and Symptom Characterization

›Core manic symptoms (DSM-5-TR Criterion B — 3 or more required, 4 if only irritable mood)

›Elevated, expansive, or irritable mood lasting 7 or more days

›Duration of any length if hospitalization required

›Clear change from baseline

›Inflated self-esteem or grandiosity

›Decreased need for sleep — feels rested after 3 hours

›Pressured speech

›Flight of ideas or subjective racing thoughts

›Distractibility

›Increased goal-directed activity or psychomotor agitation

›Excessive involvement in risky activities

›Spending sprees

›Sexual indiscretions

›Foolish investments

Precipitating Factors and Timeline

›Triggers and timeline

›Onset pattern — typically over days

›Sleep deprivation — potent manic trigger

›Goal-attainment events (marriage, promotion) — specific manic relapse trigger

›Recent stressors or major life changes

›Medication changes

›Recent antidepressant initiation (SSRIs, SNRIs, TCAs)

›Stimulant initiation (methylphenidate, amphetamines)

›Corticosteroid use

›Levodopa, isoniazid, baclofen, HIV integrase inhibitors

›Substance use

›Alcohol — comorbid in 50-60% of bipolar disorder patients

03Physical Exam/exam55

General and Behavioral Observation

›Mental status and behavioral assessment

›General appearance

›Flamboyant or inappropriate clothing

›Disheveled or poor hygiene in severe episodes

›Excessive energy or restlessness

›Psychomotor activity

›Agitation or hyperactivity

›Pressured movements

›Speech

›Rate — pressured, rapid

›Volume — loud

›Tangentiality or circumstantiality

›Flight of ideas

›Mood and affect

›Euphoric, expansive, or irritable

›Labile affect

›Thought content

›Grandiose delusions

›Paranoid ideation

›Suicidal or homicidal content

›Perceptual disturbances

›Auditory or visual hallucinations — present in >50% of bipolar I manic episodes

›Insight and judgment

›Degree of illness recognition

›Capacity for safe decision-making

Neurologic Examination

›Focused neurologic assessment

04Differential Diagnosis/ddx55

Cannot-Miss Diagnoses

›Life-threatening conditions mimicking mania

›Stimulant intoxication (cocaine, methamphetamine, MDMA)

›Urine drug screen positive

›Sympathomimetic toxidrome features

›ICD-10: T40-T43 drug intoxication codes

›Delirium from medical illness

›Fluctuating course — distinguishes from mania

›Disorientation not typical of primary mania

›ICD-10: F05 delirium

›Anti-NMDA receptor encephalitis

›Young women predominantly

›New-onset psychosis with movement disorder

›CSF pleocytosis

›ICD-10: G04.81 encephalitis

›Thyroid storm

›TSH suppressed, free T4 markedly elevated

›Diaphoresis, hyperthermia

›ICD-10: E05.5 thyroid storm

›Alcohol withdrawal — delirium tremens

›Recent alcohol cessation

›Autonomic instability, seizures

›CNS mass lesion or hemorrhage

›Focal neurologic signs

›First-episode mania age >35 raises suspicion

Important Psychiatric Alternatives

›Primary psychiatric differential

›Schizoaffective disorder

05Laboratory Tests/lt50

Essential Initial Workup

›Metabolic and safety panel

›Complete blood count

›Leukocytosis — infection, NMS

›Thrombocytopenia — valproate effect

›Anemia baseline

›Comprehensive metabolic panel

›Electrolytes — sodium critical for lithium handling

›Renal function — lithium clearance dependent on GFR

›Glucose — antipsychotic metabolic effects

›Liver function — valproate hepatotoxicity monitoring

›Thyroid-stimulating hormone

›Hypothyroidism and hyperthyroidism both cause mood symptoms

›Baseline before lithium initiation (lithium causes hypothyroidism)

›Urine drug screen

›Stimulants — cocaine, amphetamines

›Cannabis — worsens mood instability

›Phencyclidine — can cause mania-like psychosis

›Pregnancy test

›All women of childbearing age

›Valproate Category X; lithium category D — Ebstein anomaly risk

Drug Levels and Monitoring

›Mood stabilizer levels

›Serum lithium level if already prescribed

›Therapeutic range 0.8-1.2 mmol/L acutely

›Toxicity risk above 1.5 mmol/L

›Severe toxicity above 2.0 mmol/L — neurologic symptoms

›Valproic acid level if prescribed

06Diagnostic Tests/dt77

Scoring Systems

›Young Mania Rating Scale (YMRS)

›11-item clinician-rated severity scale

›Scores 0-60; higher scores indicate more severe mania

›Score >20 indicates moderate-to-severe mania

›Used for tracking treatment response over time

›Not a diagnostic tool

›Items rated include elevated mood, motor activity, sexual interest, sleep, irritability, speech, language/thought disorder, content, disruptive behavior, appearance, insight

›Mood Disorder Questionnaire (MDQ)

›13-item self-report screening tool for bipolar spectrum

›Sensitivity 73%, specificity 90% for bipolar I

›Positive screen: 7 or more items yes, symptoms co-occurred, caused moderate or severe problems

›Not validated for acute inpatient settings

›Columbia Suicide Severity Rating Scale (C-SSRS)

›Structured suicide risk assessment

›Ideation intensity subscale and behavior subscale

›Identifies high-risk features: plan, intent, access to means

›Required for all patients with suicidal ideation

Scoring Systems Additional Tools

›DSM-5-TR diagnostic criteria application

›Criterion A — distinct period of elevated/expansive/irritable mood with increased energy lasting 7+ days

›Criterion B — 3+ associated symptoms (4 if only irritable)

›Criterion C — marked functional impairment or hospitalization required

›Criterion D — not attributable to substances or medical conditions

›Severity stratification

›Mild/moderate — hypomanic features, no psychosis, preserved insight

›Severe — psychotic features, aggressive behavior, complete loss of insight

›Mixed features specifier — concurrent depressive symptoms; highest suicide risk

MRI

›Brain MRI indications in manic episode

›Indications for neuroimaging

›First episode of mania in a patient over 35 years — secondary mania concern

›Abnormal neurologic examination findings

›Atypical presentation not fitting standard bipolar pattern

›New-onset psychosis without prior psychiatric history

›Suspected encephalitis, stroke, mass lesion, or TBI

›MRI preferred over CT when neuroimaging is indicated

›Superior soft tissue resolution

›No ionizing radiation

›Better for white matter lesions and limbic system

›MRI findings in bipolar disorder research context

›White matter hyperintensities more common in bipolar vs controls

›Not diagnostic but supports disease burden

›Clinical relevance in individual patients is uncertain

›Structural changes in amygdala and hippocampus noted in studies

›Not used for individual diagnosis

›Frontal lobe lesions on MRI suggest secondary organic mania

›Especially right frontal and orbitofrontal lesions

›CT head indications

›Acute neuroimaging indications

›Head trauma with mania presentation

›First mania episode with focal neurologic findings

›Altered sensorium or acute change in consciousness

›When MRI is unavailable or contraindicated

›CT head is not routinely indicated for known bipolar disorder with typical presentation

›Evidence level: Expert consensus

›CT findings relevant to differential

›Intracranial hemorrhage — subdural, intracerebral

›Especially in elderly or anticoagulated patients

›Mass lesion — tumor, abscess

›Right frontal lesions associated with secondary mania

›Hydrocephalus

Ultrasound

›Ultrasound applications in manic episode workup

›Not routinely indicated for primary mania evaluation

›Role limited to specific clinical scenarios

›Thyroid ultrasound

›If thyroid enlargement or nodule on exam

›Hyperthyroidism confirmed with TSH and free T4; ultrasound for structural assessment

›POCUS for rapid assessment of coexisting conditions

›Cardiac function if hemodynamic instability

›IVC collapsibility for volume status if altered mental status with dehydration concern

›ECG — required diagnostic test (not ultrasound)

›Indications for ECG

›Patients over 40 years of age

›Before lithium, antipsychotic, or QTc-prolonging medication initiation

›Cardiac history, electrolyte abnormalities

›Key ECG findings

›Lithium: T-wave flattening or inversion, sinus node dysfunction, AV block

›QTc >500 ms — high torsades de pointes risk; reconsider agent selection

›Antipsychotics: QTc prolongation; ziprasidone highest risk; quetiapine and risperidone lower risk

07Disposition/dispo44

Admission Criteria

›Indications for inpatient psychiatric admission

›Absolute admission indications

›Psychotic features — hallucinations or delusions

›Active suicidal ideation or homicidal ideation

›Aggressive or violent behavior

›Severe impairment in judgment with inability to care for self

›Inability to ensure safety in outpatient setting

›First episode of mania

›Involuntary admission considerations

›When impaired judgment adversely affects capacity to consent

›Danger to self or others

›Patients who are aggressive or psychotic more likely to require involuntary admission

›Level of care

›Inpatient psychiatric unit for severe or psychotic mania

›Medical floor if organic etiology requires ongoing medical management

Observation and Short-Stay Criteria

›Observation unit considerations

›Appropriate for initial stabilization

›Mild mania responding to medication initiation

›Reliable outpatient follow-up and social support confirmed

›No psychosis, no safety concerns

›Not appropriate if safety cannot be ensured

›Reassess every 4-6 hours

Discharge Criteria

›Safe discharge requirements (all must be met)

›Clinical criteria

›Hypomania only — no full manic episode criteria

08Treatment/t140

Immediate Stabilization

›Acute agitation management — first-line

›De-escalation first

›Calm verbal approach

›Reduce environmental stimulation

›Offer oral medication preference

›Oral/sublingual agents for cooperative patients

›Lorazepam 1-2 mg PO

›Onset 30-60 minutes

›Repeat every 1-2 hours as needed

›Sublingual dexmedetomidine 120 mcg

›May increase to 180 mcg if needed

›Monitor blood pressure — hypotension risk

›Inhaled loxapine 10 mg

›Rapid onset 10-20 minutes

›Contraindicated in respiratory disease

›Intramuscular agents for uncooperative patients

›Lorazepam 1-2 mg IM

›First choice when etiology uncertain

›Haloperidol 5 mg IM

›Add diphenhydramine 25-50 mg IM to prevent acute dystonia

›Monitor QTc

›Olanzapine 10 mg IM

›Do not combine with IM lorazepam — fatal respiratory depression risk

›Effective onset 15-30 minutes

›Droperidol 5-10 mg IM

›Rapid onset

›QTc monitoring required

Acute Pharmacotherapy — Mood Stabilizers

›Lithium — first-line for classic euphoric mania

›Dosing

›300 mg TID initial dose

›Titrate to serum level 0.8-1.2 mmol/L acutely

›Allow 5 days to reach steady state

›Twice daily dosing for maintenance

›Monitoring

›Serum lithium level 5-7 days after initiation

›Serum creatinine, TSH, electrolytes at baseline

›Renal function and TSH every 6 months long-term

›Toxicity thresholds

›Levels above 1.5 mmol/L — mild toxicity (tremor, nausea, diarrhea)

›Levels above 2.0 mmol/L — severe toxicity (confusion, ataxia, seizures)

›Narrow therapeutic index — maintain hydration

›Advantages

›Only agent with demonstrated anti-suicidal properties

›Treatment of choice for classic euphoric mania

›Reduces suicide risk by 60-70%

›Contraindications and cautions

›Avoid in pregnancy (Ebstein anomaly risk)

›Renal impairment reduces clearance significantly

›Dehydration increases toxicity risk

›Valproic acid — preferred for rapid control or mixed features

›Dosing

›Loading dose 20-30 mg/kg/day IV or PO

›Preferred for acute mania — rapid titration possible

›Divided doses or extended-release formulations

›Target serum level 350-700 micromol/L trough

›Monitoring

›LFTs and CBC at baseline and periodically

›Level in 3-5 days after initiation

›Ammonia if mental status changes occur

›Key advantages

›Rapid loading enables faster response than lithium

›Preferred for mixed features and rapid cycling

›Preferred for irritable-predominant mania

›Contraindications

›Absolute contraindication in pregnancy — Category X; neural tube defects, cognitive impairment in offspring

›Liver disease

›Urea cycle disorders

Acute Pharmacotherapy — Atypical Antipsychotics

›First-line antipsychotics for acute mania (CANMAT/ISBD guidelines)

›Quetiapine

›Acute mania: 400-800 mg/day in divided doses

›Start 50 mg BID, titrate rapidly

›Sedating — useful for sleep disruption in mania

›Monitor QTc, weight, fasting glucose

›Risperidone

›2-6 mg/day in acute mania

›Start 1-2 mg/day, titrate over days

›EPS risk at higher doses

›Hyperprolactinemia risk

›Aripiprazole

›15-30 mg/day

›Less sedating — may not be preferred for severe agitation

›Low metabolic risk profile

›Akathisia risk — monitor closely

›Asenapine

›Sublingual 5-10 mg BID

›No first-pass metabolism

›Avoid food and drink 10 minutes after sublingual dose

›Cariprazine

›3-6 mg/day

›Effective for both mania and bipolar depression

›Paliperidone

›3-12 mg/day

›Active metabolite of risperidone

›Olanzapine — second-line due to metabolic effects

›10-20 mg/day for acute mania

›Highly effective but causes significant weight gain and metabolic syndrome

›Monitor weight, fasting glucose, lipids

›Class I recommendation for mania; limited by long-term adverse effects

Combination Therapy and Refractory Mania

›Combination pharmacotherapy for severe mania

›Indications

›Severe mania unresponsive to monotherapy

›Psychotic features present

›Rapid response required

›Preferred combinations (CANMAT/ISBD)

›Lithium plus quetiapine

›Lithium plus aripiprazole

›Lithium plus risperidone

›Lithium plus asenapine

›Valproate plus quetiapine

›Valproate plus risperidone

›Combination more effective than monotherapy for severe mania

›Class I recommendation

›Refractory mania management

›Electroconvulsive therapy (ECT)

›Bifrontal or bitemporal electrode placement

›Indicated for severe refractory mania, psychosis, or aggression

›Rapidly effective — response within 1-2 weeks

›Consider if pharmacotherapy fails or intolerable side effects

›Clozapine

›Reserved for treatment-resistant bipolar disorder

›Requires REMS monitoring — absolute neutrophil count monitoring

Medications to Avoid in Acute Mania

›Contraindicated treatments

›Antidepressant monotherapy — contraindicated in acute mania and mixed features

›SSRIs, SNRIs, TCAs all risk precipitating mania

›If already on antidepressant, discontinue during acute manic episode

›Stimulants — discontinue (methylphenidate, amphetamines)

›Gabapentin — no evidence for acute mania; may worsen

›Lamotrigine — not effective for acute mania; risk of Stevens-Johnson syndrome if titrated too rapidly

Maintenance Therapy

›Long-term mood stabilization

›Pharmacotherapy continued indefinitely

›25% relapse in year 1 even with treatment

›More than 70% relapse within 5 years without treatment

›Lithium cornerstone of maintenance

›Maintenance target level 0.6-0.8 mmol/L

›Anti-suicidal properties unique to lithium

›Psychosocial interventions

›Cognitive behavioral therapy for bipolar disorder

›Interpersonal and social rhythm therapy (IPSRT) — targets circadian disruption

›Family-focused therapy

›Psychoeducation about early warning signs

09Special Populations/sp81

Pregnancy

›Medication safety in pregnancy

›Valproate — absolutely contraindicated throughout pregnancy

›Neural tube defects (1-2% risk)

›Cardiac defects, cleft palate

›Cognitive impairment in offspring — IQ reduction of 8-10 points

›Category X — never use in women who may become pregnant

›Lithium — use with caution (Category D)

›Ebstein anomaly risk (tricuspid valve malformation) — absolute risk low (~0.1%)

›Risk-benefit discussion required

›Fetal echocardiography recommended if exposed in first trimester

›Lithium levels change throughout pregnancy — increased monitoring required

›Levels drop at delivery — toxicity risk postpartum

›Lamotrigine — relatively safer option for maintenance in pregnancy

›Cleft palate risk at higher doses — use lowest effective dose

›Dosing requirements increase in pregnancy due to increased clearance

›Atypical antipsychotics in pregnancy

›Quetiapine, olanzapine — relatively more data available

›Neonatal adaptation syndrome possible in third trimester

›Neonatal metabolic monitoring recommended

›Peripartum considerations

›Postpartum period — highest risk time for bipolar relapse

›25-50% of women with bipolar disorder experience postpartum mania or psychosis

›Breastfeeding considerations — lithium excreted in breast milk

›Multidisciplinary team required

›Psychiatry, obstetrics, neonatology

›Pregnancy test before initiating any mood stabilizer

Geriatric

›Late-onset mania considerations

›Secondary mania more likely in elderly first-episode presentation

›Organic workup mandatory — stroke, mass, dementia, thyroid, medications

›Vascular mania from subcortical white matter disease

›First mania over age 50 — MRI brain and full medical workup essential

›Pharmacologic modifications in elderly

›Lithium

›Reduced renal clearance — use lower doses

›Toxicity at lower serum levels than in younger patients

›Target level 0.4-0.7 mmol/L in elderly

›Increased risk of neurotoxicity even at therapeutic levels

›Increased falls and cognitive impairment risk

›Valproate

›Higher risk of thrombocytopenia and hepatotoxicity

›Protein binding changes — free drug levels may be higher

›Antipsychotics

›Increased EPS and tardive dyskinesia risk

›QTc prolongation risk higher

›Black box warning — increased mortality in elderly with dementia-related psychosis

›Avoid in Lewy body dementia — life-threatening sensitivity to antipsychotics

›Benzodiazepines

›Increased falls, cognitive impairment, paradoxical agitation

›Use lowest dose for shortest duration

›Comorbidity management

›Drug interactions with cardiac medications common

›Lithium with NSAIDs, ACE inhibitors, diuretics — increases lithium levels

›Cognitive impairment can mask insight deficit from mania

Pediatrics

›Diagnosis and presentation in children and adolescents

›Bipolar disorder is less common before age 12

›Diagnosis requires same DSM-5-TR criteria as adults

›Episodic nature must be established

›Presentation differences in youth

›More irritable-predominant mania than euphoric

›Rapid cycling and mixed features more common in adolescents

›High comorbidity with ADHD — distinguish ADHD hyperactivity from mania

›Comorbidity with anxiety disorders, substance use

›Avoid overdiagnosis — confirm episodic nature before bipolar diagnosis

›Pharmacotherapy in pediatrics

›FDA-approved agents for acute mania in youth

›Lithium — approved age 12 and older

›Weight-based dosing; target level 0.8-1.2 mmol/L

›Risperidone — approved age 10 and older

›Quetiapine — approved age 10 and older

›Aripiprazole — approved age 10 and older

›Asenapine — approved age 10 and older

›Valproate — widely used off-label in adolescents

›Teratogenic risk in adolescent females — require contraception counseling

›Polycystic ovary syndrome association with valproate in adolescent girls

›Antipsychotics — higher metabolic risk in youth than adults

›Weight gain especially pronounced

›Metabolic monitoring required

›Safety and consent

›Parental involvement in treatment decisions

›Child protective services if safety concerns for dependent children

›School and social supports

10Background/b85

Epidemiology

›Prevalence and incidence

›Bipolar disorder affects approximately 1-3% of the global population

›Bipolar I disorder: approximately 1% lifetime prevalence

›Bipolar II disorder: approximately 0.4-1.1% lifetime prevalence

›Equal prevalence in men and women

›Age of onset

›Mean onset late teens to mid-twenties

›Median age of onset 25 years

›Early onset (before age 20) associated with worse prognosis

›Morbidity and mortality

›Suicide risk 20-30x the general population

›Standardized mortality ratio approximately 2x general population

›Years lived with disability among highest of all psychiatric disorders

›Genetic epidemiology

›Heritability 60-80%

›First-degree relative risk 5-10% vs 1% general population

›Twin concordance 40-70% in monozygotic twins

›Comorbidities

›Alcohol use disorder in 50-60% of patients

›Anxiety disorders in 50% of patients

›ADHD comorbidity in 20-30%

›Cannabis use disorder increasingly recognized

Pathophysiology

›Neurobiological mechanisms

›Monoamine dysregulation

›Dopaminergic hyperactivity in mania — mesolimbic pathway

›Noradrenergic hyperactivity contributes to agitation and arousal

›Serotonergic dysregulation affects mood cycling

›Circadian rhythm disruption

›Social zeitgeber theory — life events disrupt biological rhythms

›Circadian gene variants implicated (CLOCK, ARNTL)

›Sleep-wake cycle disruption is both trigger and symptom of mania

›Neuroinflammation

›Elevated pro-inflammatory cytokines (IL-6, TNF-alpha) during episodes

›Microglial activation in postmortem studies

›Inflammatory pathway overlap with medical comorbidities

›Structural and functional neuroimaging findings

›Prefrontal cortical thinning

›Amygdala hyperactivity — emotional dysregulation

›Hippocampal volume reduction with episode number

›White matter hyperintensities — vascular and inflammatory

›Genetic architecture

›Polygenic risk architecture

›Overlap with schizophrenia, MDD, and ADHD at genetic level

›ANK3, CACNA1C, SHANK2 among implicated genes

›Kindling hypothesis

›Early episodes require environmental triggers

›Later episodes can occur spontaneously (kindling effect)

›Supports early and sustained treatment to prevent progression

›Episode number predicts severity and treatment resistance

Therapeutic Considerations

›Evidence base for acute mania treatment

›Lithium — Class I recommendation for acute mania and maintenance

›Only agent with proven anti-suicidal properties

›Number needed to treat for mania prevention: 3-5

›Reduces suicide risk by 60-70% (JAMA 2023)

›Valproate — Class I recommendation for acute mania

›Particularly effective for mixed features and rapid cycling

›Faster onset than lithium due to loading capacity

›Atypical antipsychotics — Class I for acute mania

›Quetiapine, risperidone, aripiprazole, asenapine, cariprazine — all first-line

›Combination lithium/valproate plus antipsychotic superior to monotherapy for severe mania

›ECT — Class I for severe refractory mania

›Response rates 80-90% in acute mania

›Bifrontal preferred for mania

›Treatment gaps and challenges

›Average delay to bipolar diagnosis is 5-10 years from symptom onset

›Often initially misdiagnosed as unipolar depression

›Antidepressant monotherapy before correct diagnosis worsens outcomes

›Medication adherence is the primary driver of relapse

›Lack of insight (anosognosia) is central to non-adherence

›Psychoeducation and family involvement critical

›Substance use comorbidity significantly worsens prognosis

›Alcohol and cannabis use disorder most common

›Integrated dual diagnosis treatment required

›Classification systems

›ICD-10: F31.x Bipolar affective disorder

›F31.0 — current episode hypomanic

›F31.1 — current episode manic without psychotic symptoms

›F31.2 — current episode manic with psychotic symptoms

›F31.6 — current episode mixed

›DSM-5-TR specifiers

›With psychotic features

›With mixed features

›With rapid cycling

›With anxious distress

›With seasonal pattern

11Patient Discharge Instructions/pdi33

copy discharge instructions

›Discharge instructions for Bipolar Disorder — Manic Episode

›What to do at home

›Take all prescribed medications exactly as directed

›Do not stop or change any medication without contacting your doctor

›Keep a consistent sleep schedule — sleep deprivation can trigger another episode

›Attend your psychiatry follow-up appointment within 1 week

›Have a trusted person check in with you daily

›Medications prescribed at discharge

›Take at the same time each day

›If lithium was started, get a blood level drawn in 5-7 days as scheduled

›If valproate was started, get a blood level drawn in 3-5 days as scheduled

›Do not take ibuprofen, naproxen, or other NSAIDs if on lithium — they increase lithium levels and toxicity risk

›Things to avoid

›Alcohol — worsens mood instability and interacts with medications

›Cannabis — worsens mood swings

›All recreational drugs or stimulants

›Caffeine in large amounts — worsens agitation and insomnia

›Starting any new medication without telling your psychiatrist

›Warning signs to monitor

›Racing thoughts, needing less sleep, feeling unusually energetic or irritable

›Feeling like you do not need your medications

›Spending more money than usual or making impulsive decisions

›Hearing or seeing things others do not

›Return to emergency immediately if

›Thoughts of harming yourself or others

›Inability to sleep for more than 48 hours

›Aggressive behavior or loss of control

12References/r36

Guidelines and Key Sources

›Primary clinical guidelines

›CANMAT and ISBD 2018 Recommendations for the Management of Patients with Bipolar Disorder

›Yatham LN et al. Bipolar Disorders 2018

›First-line agents for acute mania: lithium, valproate, quetiapine, risperidone, aripiprazole, asenapine, cariprazine, paliperidone

›VA/DoD Clinical Practice Guideline for Management of Bipolar Disorder 2023

›Arnold MJ. American Family Physician 2024

›Evidence-based guidance for lithium and combination therapy

›RANZCP Clinical Practice Guidelines for Mood Disorders 2020

›Malhi GS et al. Bipolar Disorders 2020

›Mixed features and psychotic mania guidance

›Landmark studies and review articles

›Nierenberg AA et al. Diagnosis and Treatment of Bipolar Disorder: A Review. JAMA 2023

›Comprehensive review including anti-suicidal properties of lithium

›Combination therapy superiority for severe mania

›Singh B et al. Bipolar Disorder. Lancet 2025

›Updated epidemiology, pathophysiology, and treatment evidence

›Carvalho AF, Firth J, Vieta E. Bipolar Disorder. NEJM 2020

›Pathophysiology and therapeutic framework

›McIntyre RS et al. Bipolar Disorders. Lancet 2020

›Global burden, neuroinflammation, treatment-resistance concepts

›Miller JN, Black DW. Bipolar Disorder and Suicide: A Review. Current Psychiatry Reports 2020

›Suicide risk quantification — 20-30x general population

›Mixed features and highest acute risk

Diagnostic Tools and Resources

›Diagnostic instruments

›DSM-5-TR (American Psychiatric Association 2022)

›Diagnostic criteria and specifiers for bipolar I disorder

Learn More: Bipolar Disorder (Manic Episode)→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.